Vaccine 33 (2015) 523–526

Contents lists available at ScienceDirect

Vaccine journal homepage: www.elsevier.com/locate/vaccine

Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus Vilasack Thammavongsa, Sabine Rauch, Hwan Keun Kim, Dominique M. Missiakas, Olaf Schneewind ∗ Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA

a r t i c l e

i n f o

Article history: Received 16 July 2014 Received in revised form 22 October 2014 Accepted 27 November 2014 Available online 6 December 2014 Keywords: Staphylococcus aureus Staphylococcal protein A Monoclonal antibody Neonatal bacteremia and meningitis Protective immunity Recurrent infection

a b s t r a c t Staphylococcus aureus is a cause of sepsis and meningitis in very-low-birth-weight (VLBW) infants. Clinical trials with S. aureus specific antibodies failed to protect VLBW neonates, which may be due to the immune evasive attributes of staphylococcal protein A (SpA). Here we show that mouse monoclonal antibody SpAKKAA -mAb 3F6, which neutralizes the immunoglobulin Fc␥-binding and B cell receptor crosslinking attributes of SpA, protects neonatal mice against S. aureus sepsis and raises protective immunity against subsequent staphylococcal infection. We developed a humanized SpAKKAA -mAb that protects neonatal mice against S. aureus sepsis and may therefore be subjected to clinical testing in VLBW neonates. © 2014 Elsevier Ltd. All rights reserved.

1. Introduction Approximately 60,000 infants per year in the United States are very-low-birth-weight (VLBW), defined as

Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus.

Staphylococcus aureus is a cause of sepsis and meningitis in very-low-birth-weight (VLBW) infants. Clinical trials with S. aureus specific antibodies ...
685KB Sizes 2 Downloads 9 Views